Skip to search formSkip to main contentSkip to account menu

Inhalant Solution

Known as: Inhalation Solutions, Inhalant Solution [Dose Form], Inhalant Solution Dosage Form 
Liquid medication intended to be inhaled.
National Institutes of Health

Related topics

Related topics

35 relations
Acetylcysteine 200 MG/ML Inhalant SolutionAlbuterol 0.833 MG/ML / Ipratropium Bromide 0.167 MG/ML Inhalant SolutionAztreonam 75 MG/ML Inhalant Solution [Cayston]Aztreonam Inhalant Solution [Cayston]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Aztreonam Lysine for Inhalation Solution in Cystic Fibrosis
Aztreonam is a monobactam antibacterial with bactericidal activity against a wide range of aerobic Gram-negative bacteria… 
Review
2011
Review
2011
Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis
An aerosol form of aztreonam lysinate has recently been developed as a treatment for cystic fibrosis patients suffering from… 
Review
2010
Review
2010
Aztreonam Lysine for Inhalation Solution
Aztreonam is a monobactam antibacterial with bactericidal activity against a wide range of aerobic Gram-negative bacteria… 
2008
2008
[Microorganisms in home-care inhalation devices].
Contamination of inhalation equipment used at home, cleaning procedures, and the occurrence of potentially pathogenic micro… 
2007
2007
Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
2007
2007
Compatibility of arformoterol tartrate inhalation solution with three nebulized drugs
ABSTRACT Objective: Arformoterol tartrate inhalation solution (15 μg/2 mL) is approved for the twice-daily, long-term maintenance… 
2007
2007
Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol.
Patients suffering from cystic fibrosis (CF) often need to inhale multiple doses of different nebulizable drugs per day. Patients… 
Review
2005
Review
2005
Iloprost inhalation solution for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a condition that is characterised by increased pulmonary arterial pressure and vascular… 
2005
2005
Sputum induction as a research tool for the study of human respiratory mucus
1979
1979
Inhibition of exercise-induced bronchoconstriction by nebulised sodium cromoglycate in patients with bronchial asthma.
In this double blind study, 10 patients with bronchial asthma underwent exercise challenge on five occasions. The first of these… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)